These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

624 related articles for article (PubMed ID: 28739932)

  • 1. CDCP1 drives triple-negative breast cancer metastasis through reduction of lipid-droplet abundance and stimulation of fatty acid oxidation.
    Wright HJ; Hou J; Xu B; Cortez M; Potma EO; Tromberg BJ; Razorenova OV
    Proc Natl Acad Sci U S A; 2017 Aug; 114(32):E6556-E6565. PubMed ID: 28739932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDCP1 cleavage is necessary for homodimerization-induced migration of triple-negative breast cancer.
    Wright HJ; Arulmoli J; Motazedi M; Nelson LJ; Heinemann FS; Flanagan LA; Razorenova OV
    Oncogene; 2016 Sep; 35(36):4762-72. PubMed ID: 26876198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FBXL14 abolishes breast cancer progression by targeting CDCP1 for proteasomal degradation.
    Cui YH; Kim H; Lee M; Yi JM; Kim RK; Uddin N; Yoo KC; Kang JH; Choi MY; Cha HJ; Kwon OS; Bae IH; Kim MJ; Kaushik N; Lee SJ
    Oncogene; 2018 Oct; 37(43):5794-5809. PubMed ID: 29973690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PDGFRβ/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer.
    Forte L; Turdo F; Ghirelli C; Aiello P; Casalini P; Iorio MV; D'Ippolito E; Gasparini P; Agresti R; Belmonte B; Sozzi G; Sfondrini L; Tagliabue E; Campiglio M; Bianchi F
    BMC Cancer; 2018 May; 18(1):586. PubMed ID: 29792166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers.
    Turdo F; Bianchi F; Gasparini P; Sandri M; Sasso M; De Cecco L; Forte L; Casalini P; Aiello P; Sfondrini L; Agresti R; Carcangiu ML; Plantamura I; Sozzi G; Tagliabue E; Campiglio M
    Oncotarget; 2016 Oct; 7(43):69649-69665. PubMed ID: 27626701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CUB domain-containing protein 1, a prognostic factor for human pancreatic cancers, promotes cell migration and extracellular matrix degradation.
    Miyazawa Y; Uekita T; Hiraoka N; Fujii S; Kosuge T; Kanai Y; Nojima Y; Sakai R
    Cancer Res; 2010 Jun; 70(12):5136-46. PubMed ID: 20501830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth.
    Woodcock CC; Huang Y; Woodcock SR; Salvatore SR; Singh B; Golin-Bisello F; Davidson NE; Neumann CA; Freeman BA; Wendell SG
    J Biol Chem; 2018 Jan; 293(4):1120-1137. PubMed ID: 29158255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADAM9 enhances CDCP1 by inhibiting miR-1 through EGFR signaling activation in lung cancer metastasis.
    Chiu KL; Lin YS; Kuo TT; Lo CC; Huang YK; Chang HF; Chuang EY; Lin CC; Cheng WC; Liu YN; Lai LC; Sher YP
    Oncotarget; 2017 Jul; 8(29):47365-47378. PubMed ID: 28537886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of inside-out β1-integrin activation by CDCP1.
    Pollan SG; Huang F; Sperger JM; Lang JM; Morrissey C; Cress AE; Chu CY; Bhowmick NA; You S; Freeman MR; Spassov DS; Moasser MM; Carter WG; Satapathy SR; Shah K; Knudsen BS
    Oncogene; 2018 May; 37(21):2817-2836. PubMed ID: 29511352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CUB-domain-containing protein 1 (CDCP1) activates Src to promote melanoma metastasis.
    Liu H; Ong SE; Badu-Nkansah K; Schindler J; White FM; Hynes RO
    Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1379-84. PubMed ID: 21220330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HRD1 inhibits fatty acid oxidation and tumorigenesis by ubiquitinating CPT2 in triple-negative breast cancer.
    Guo X; Wang A; Wang W; Wang Y; Chen H; Liu X; Xia T; Zhang A; Chen D; Qi H; Ling T; Piao HL; Wang HJ
    Mol Oncol; 2021 Feb; 15(2):642-656. PubMed ID: 33207079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer.
    Harrington BS; He Y; Davies CM; Wallace SJ; Adams MN; Beaven EA; Roche DK; Kennedy C; Chetty NP; Crandon AJ; Flatley C; Oliveira NB; Shannon CM; deFazio A; Tinker AV; Gilks CB; Gabrielli B; Brennan DJ; Coward JI; Armes JE; Perrin LC; Hooper JD
    Br J Cancer; 2016 Feb; 114(4):417-26. PubMed ID: 26882065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACSL4-Mediated Membrane Phospholipid Remodeling Induces Integrin β1 Activation to Facilitate Triple-Negative Breast Cancer Metastasis.
    Qiu Y; Wang X; Sun Y; Jin T; Tang R; Zhou X; Xu M; Gan Y; Wang R; Luo H; Liu M; Tang X
    Cancer Res; 2024 Jun; 84(11):1856-1871. PubMed ID: 38471082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myoferlin regulates cellular lipid metabolism and promotes metastases in triple-negative breast cancer.
    Blomme A; Costanza B; de Tullio P; Thiry M; Van Simaeys G; Boutry S; Doumont G; Di Valentin E; Hirano T; Yokobori T; Gofflot S; Peulen O; Bellahcène A; Sherer F; Le Goff C; Cavalier E; Mouithys-Mickalad A; Jouret F; Cusumano PG; Lifrange E; Muller RN; Goldman S; Delvenne P; De Pauw E; Nishiyama M; Castronovo V; Turtoi A
    Oncogene; 2017 Apr; 36(15):2116-2130. PubMed ID: 27775075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic Ras/ERK signaling activates CDCP1 to promote tumor invasion and metastasis.
    Uekita T; Fujii S; Miyazawa Y; Iwakawa R; Narisawa-Saito M; Nakashima K; Tsuta K; Tsuda H; Kiyono T; Yokota J; Sakai R
    Mol Cancer Res; 2014 Oct; 12(10):1449-59. PubMed ID: 24939643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer.
    Camarda R; Zhou AY; Kohnz RA; Balakrishnan S; Mahieu C; Anderton B; Eyob H; Kajimura S; Tward A; Krings G; Nomura DK; Goga A
    Nat Med; 2016 Apr; 22(4):427-32. PubMed ID: 26950360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer.
    Chen B; Wang J; Dai D; Zhou Q; Guo X; Tian Z; Huang X; Yang L; Tang H; Xie X
    J Exp Clin Cancer Res; 2017 May; 36(1):65. PubMed ID: 28494797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ADAM9 enhances CDCP1 protein expression by suppressing miR-218 for lung tumor metastasis.
    Chiu KL; Kuo TT; Kuok QY; Lin YS; Hua CH; Lin CY; Su PY; Lai LC; Sher YP
    Sci Rep; 2015 Nov; 5():16426. PubMed ID: 26553452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of autophagy by CUB domain-containing protein 1 signaling is essential for anchorage-independent survival of lung cancer cells.
    Uekita T; Fujii S; Miyazawa Y; Hashiguchi A; Abe H; Sakamoto M; Sakai R
    Cancer Sci; 2013 Jul; 104(7):865-70. PubMed ID: 23510015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatty acid binding protein 5 promotes metastatic potential of triple negative breast cancer cells through enhancing epidermal growth factor receptor stability.
    Powell CA; Nasser MW; Zhao H; Wochna JC; Zhang X; Shapiro C; Shilo K; Ganju RK
    Oncotarget; 2015 Mar; 6(8):6373-85. PubMed ID: 25779666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.